Nexalin Technology, Inc. (NXL)

Market Cap	11.46M
Revenue (ttm)	158,860
Net Income (ttm)	-4.94M
Shares Out	7.59M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	932,817
Open	1.640
Previous Close	1.660
Day's Range	1.440 - 1.720
52-Week Range	0.253 - 4.050
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 8, 2024

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The compan...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 16, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NXL

Financial Performance

In 2023, NXL's revenue was $110,748, a decrease of -91.62% compared to the previous year's $1.32 million. Losses were -$4.65 million, 173.8% more than in 2022.